Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kimberly T. Perry"'
Autor:
Ashwin Chatwani, Mark Martens, David A. Grimes, Molly Chatterjee, Melvin Noah, Marion M. Stamp-Cole, Kimberly T. Perry, the Cefmetazole Study Group
Publikováno v:
Infectious Diseases in Obstetrics and Gynecology, Vol 3, Iss 1, Pp 28-33 (1995)
Objective: The purpose of this study was to compare the clinical efficacy and safety of cefmetazole given by IV push with that of parenterally administered cefoxitin for the treatment of endometritis following cesarean delivery.
Externí odkaz:
https://doaj.org/article/b3135638a55a4378ad36505fd8055152
Autor:
Thomas S. Ahern, James T. VanderLugt, Kimberly T. Perry, Thomas Mattioni, David F. Torchiana, Peter R. Kowey, Stephen Denker, Linda K. Wakefield
Publikováno v:
Circulation. 100:369-375
Background —Atrial arrhythmias occur commonly after cardiac surgery and are a cause of significant morbidity and increased hospital costs, yet there is no well-studied treatment strategy to deal with them expeditiously. The purpose of this study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::228cbaecb82b0ba63818713d340cc0e9
https://doi.org/10.1161/01.cir.100.4.369
https://doi.org/10.1161/01.cir.100.4.369
Autor:
Kimberly T. Perry, Pierre Abi-Mansour, Ronald J. McCowan, Peter A. Carberry, Richard W. Henthorn, George H. Dunn
Publikováno v:
American Heart Journal. 136:632-642
Background A study was conducted to determine the efficacy and safety of ibutilide fumarate versus placebo in the acute termination of atrial flutter and fibrillation. Methods and Results Two hundred sixty-two patients aged 28 to 88 years with atrial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ea1ff8dfbb90bbb5e3d274297aa3f26
https://doi.org/10.1016/s0002-8703(98)70010-9
https://doi.org/10.1016/s0002-8703(98)70010-9
Autor:
Linda K. Wakefield, Kenneth A. Ellenbogen, James T. VanderLugt, Bruce S. Stambler, David M. Gilligan, Mark A. Wood, Kimberly T. Perry
Publikováno v:
American Heart Journal. 135:1048-1054
Background: Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress induci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5facb869a2d2cc45aa81ace599cb569
https://doi.org/10.1016/s0002-8703(98)70071-7
https://doi.org/10.1016/s0002-8703(98)70071-7
Autor:
Bruce S. Stambler, James T. VanderLugt, William R. Lewis, Peter R. Kowey, Peter A. Carberry, Kimberly T. Perry, Annabelle Santos Volgman, George H. Dunn
Publikováno v:
Journal of the American College of Cardiology. 31:1414-1419
Objectives. This multicenter study compared the efficacy and safety of ibutilide versus procainamide for conversion of recent-onset atrial flutter or fibrillation. Background. Ibutilide fumarate is an intravenous (IV) class III antiarrhythmic agent t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95ef0d255908cf3b08d59b43c2c6e001
https://doi.org/10.1016/s0735-1097(98)00078-3
https://doi.org/10.1016/s0735-1097(98)00078-3
Autor:
Kimberly T. Perry
Publikováno v:
Drug Information Journal. 31:729-736
In drug development from mouse to man, one of the primary goals of the Phase I studies is to estimate the maximum tolerated dose (MTD). Two considerations in designing Phase I studies are to treat as few patients as possible at doses much above the M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9e3aa989c1db991d96a26ebb85fc991
https://doi.org/10.1177/009286159703100313
https://doi.org/10.1177/009286159703100313
Autor:
Bruce S. Stambler, Linda K. Wakefield, Kenneth A. Ellenbogen, Mark A. Wood, James T. VanderLugt, Kimberly T. Perry
Publikováno v:
Circulation. 94:1613-1621
Background Currently available antiarrhythmic drugs have limited efficacy for acute termination of atrial fibrillation and flutter, especially if the arrhythmia is not of recent onset. The purpose of this multicenter study was to determine the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d420578a9f0a467926b3ea8ba06927e
https://doi.org/10.1161/01.cir.94.7.1613
https://doi.org/10.1161/01.cir.94.7.1613
Autor:
James T. Vanderlugtt, Marc D. Meissner, Robert G. Zoble, Kimberly T. Perry, Bruce S. Stambler, Mark A. Wood, Philip T. Sager, Robert C. Wesley, Ibutilide Investigators, Kenneth A. Ellenbogen, Linda K. Wakefield
Publikováno v:
Journal of the American College of Cardiology. 28:130-136
Currently available antiarrhythmic drugs have limited efficacy for short-term, rapid termination of atrial fibrillation and atrial flutter.Ibutilide fumarate is an investigational class III antiarrhythmic agent that prolongs repolarization by increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48edf7201b987f134e770dd45224ad91
https://doi.org/10.1016/0735-1097(96)00121-0
https://doi.org/10.1016/0735-1097(96)00121-0